Merck KGaA (Germany) and F. Hoffmann-La Roche Ltd. (Switzerland) are Leading Players in the Biomarkers Market
The global biomarkers market is expected to reach USD 104.0 billion in 2028 from USD 59.1 billion in 2023 at a CARG of 12.0%. Factors responsible for the growth in the biomarkers market is the extensive R&D efforts by leading players, rising adoption of biomarkers in drug discovery, ongoing strategic alliances in biomarkers discovery and increasing prevalence of diseases like cancer.
Prominent players operating in the biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).
To know about the assumptions considered for the study download the pdf brochure
MERCK KGaA (GERMANY)
Merck KGaA is the leading player in the biomarkers market and accounted for the largest share of 3-4% in 2022. The company’s life science business segment is a leading global supplier of products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. The company operates the biomarkers market through the life science business segment. In July 2021, the company announced to invest USD 236.6 million at global headquarters in Darmstadt by building a new Translational Science Center for the Healthcare business sector. As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies. Such strategies enhanced its position in the biomarker market.
F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
F. Hoffmann-La Roche is the leading player in the biomarkers market and accounted for the second largest share of 2-3% in 2022. The company majorly focuses on organic growth strategies such as product innovations to enhance its position in the biomarkers market. The company has a broad customer base, which includes biopharmaceutical, academic, and research institutes. The company has extensive geographic coverage in the US, Europe, the Asia Pacific, and the Middle East & Africa. The company operates in the biomarkers market through the Diagnostics Division segment. In the past three years, the company mainly focused on product innovations to enhance its position in the biomarkers market. The product launches catered to various disease indications, including different types of cancers, cardiovascular diseases, and infectious diseases such as COVID-19. For instance, in April 2021, the company launched two cardiac biomarker tests. These gold standard biomarkers support cardiovascular disease management and can help clinicians diagnose heart attacks and manage heart failure.
Related Reports:
Biomarkers Market by Product & Service (Consumable, Service, Software), Type (Safety, Efficacy, Validation), Disease (Cancer, Infectious, Neurological), Application (Diagnostics, Drug Discovery, Personalized Medicine), Region - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
